Della Torre Laura, Nebbioso Angela, Stunnenberg Hendrik G, Martens Joost H A, Carafa Vincenzo, Altucci Lucia
Department of Precision Medicine, Università Degli Studi Della Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University, 6525 GA Nijmegen, The Netherlands.
Cancers (Basel). 2021 Feb 8;13(4):684. doi: 10.3390/cancers13040684.
Regulated cell death mechanisms are essential for the maintenance of cellular homeostasis. Evasion of cell death is one of the most important hallmarks of cancer. Necroptosis is a caspase independent form of regulated cell death, investigated as a novel therapeutic strategy to eradicate apoptosis resistant cancer cells. The process can be triggered by a variety of stimuli and is controlled by the activation of RIP kinases family as well as MLKL. The well-studied executor, RIPK1, is able to modulate key cellular events through the interaction with several proteins, acting as strategic crossroads of several molecular pathways. Little evidence is reported about its involvement in tumorigenesis. In this review, we summarize current studies on the biological relevance of necroptosis, its contradictory role in cancer and its function in cell fate control. Targeting necroptosis might be a novel therapeutic intervention strategy in anticancer therapies as a pharmacologically controllable event.
受调控的细胞死亡机制对于维持细胞内稳态至关重要。逃避细胞死亡是癌症最重要的特征之一。坏死性凋亡是一种不依赖半胱天冬酶的受调控细胞死亡形式,作为一种根除抗凋亡癌细胞的新型治疗策略而被研究。该过程可由多种刺激触发,并受RIP激酶家族以及混合谱系激酶结构域样蛋白(MLKL)的激活控制。研究充分的执行者RIPK1能够通过与多种蛋白质相互作用来调节关键的细胞事件,充当多种分子途径的战略交叉点。关于其参与肿瘤发生的报道较少。在本综述中,我们总结了目前关于坏死性凋亡的生物学相关性、其在癌症中的矛盾作用及其在细胞命运控制中的功能的研究。作为一种药理学上可控的事件,靶向坏死性凋亡可能是抗癌治疗中的一种新型治疗干预策略。